In the recent collaboration of Wyeth Pharmaceuticals (a Wyeth division) with the Health Ministry of Scotland, the creation of the Translational Medicine Research Collaboration (TMRC) was announced.
This is a collaboration that Wyeth has invested almost $86 million dollars. TMRC which will comprise the four major medical universities in Scotland (Aberdeen, Dundee, Edinburgh and Glasgow), Wyeth Pharmaceuticals, Scottish Enterprise and the National Health Service (NHS); will work more on translational medicine.
Translational medicine is a new field that integrates the study of the elements of disease with the development of novel therapies and diagnostics. A goal of these studies is the identification of “biomarkers” or specific signals within patient populations that can be used to select the best therapy for an individual patient. An important outcome of the work of the TMRC is speedier, more efficient and more effective clinical testing of new therapies where a candidate drug is studied in smaller, better defined patient groups.
Wyeth has been known for being an active leader in developing drugs in a number of disease areas: oncology, musculoskeletal biology, metabolic diseases and Alzheimer’s disease. Once more it assumed a leadershiprole in Translational Medicine.
Read Wyeth’s press release.
Comment Preview